Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.

MLA

Shengyuan Luo, et al. “Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.” Journal of the American Heart Association, vol. 11, no. 18, Sept. 2022, pp. 1–10. EBSCOhost, https://doi.org/10.1161/JAHA.122.025198.

APA

Shengyuan Luo, Vasbinder, A., Du-Fay- de- Lavallaz, J. M., D. Gomez, J. M., Suboc, T., Anderson, E., Tekumulla, A., Shadid, H., Berlin, H., Pan, M., Azam, T. U., Khaleel, I., Padalia, K., Meloche, C., O, H. P., Catalan, T., Blakely, P., Launius, C., Amadi, K.-M., & Pop-Busui, R. (2022). Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19. Journal of the American Heart Association, 11(18), 1–10. https://doi.org/10.1161/JAHA.122.025198

Chicago

Shengyuan Luo, Alexi Vasbinder, Jeanne M. Du-Fay- de- Lavallaz, Joanne Michelle D. Gomez, Tisha Suboc, Elizabeth Anderson, Annika Tekumulla, et al. 2022. “Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.” Journal of the American Heart Association 11 (18): 1–10. doi:10.1161/JAHA.122.025198.